TVRD

News

globenewswire.comTvardi Therapeutics to Participate in Upcoming Investor Eventsglobenewswire.comMay 21

globenewswire.comTvardi Therapeutics Announces First Quarter 2026 Results and Provides Business Updateglobenewswire.comMay 8

defenseworld.netBrokerages Set Tvardi Therapeutics, Inc. (NASDAQ:TVRD) PT at $55.50defenseworld.netApr 24

globenewswire.comTvardi Therapeutics to Participate in the Raymond James Biotech Innovation Symposiumglobenewswire.comApr 2

globenewswire.comTvardi Therapeutics Announces Fourth Quarter and Full-Year 2025 Results and Provides Business Updateglobenewswire.comMar 31

Trade TVRD

About Tvardi Therapeutics, Inc.

Tvardi Therapeutics operates as an advanced biopharmaceutical company, specializing in the creation of innovative, orally delivered small molecule treatments. These therapies are designed to modulate the STAT3 pathway, with the objective of tackling fibrosis-related illnesses that currently suffer from a substantial lack of effective medical solutions. Their flagship compound, TTI-101, is presently progressing through Phase 2 clinical studies for its potential in treating both idiopathic pulmonary fibrosis (IPF) and hepatocellular carcinoma (HCC).

CEO: Imran Alibhai
IPO Date: Apr 16, 2025

Market Data

Open: $2.60
High: $2.67
Low: $2.48
Volume: 103.5K
Avg Volume: 52.2K
52W High: $43.65
52W Low: $2.48

Valuation

Market Cap: $25M
Enterprise Value: $5.0M
Dividend Yield: 0.00%

Financials

Free Cash Flow: $-23M
Revenue: $0
Net Income: $-18M
Cash: $21M
Debt: $201k

Events

EarningsAug 13

EPS est. -0.70444